Protocol Ledger

NCT03517969 · Phase II · ACTIVE NOT RECRUITING

M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Interventional Phase II clinical trial protocol NCT03517969 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-05-29 Enrollment: 73 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03517969
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)73 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03517969
Protocol FieldVerified Registry Value
NCT IdentifierNCT03517969
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment73 participants (ACTUAL)
Registered Start Date2019-05-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI